Sparking gains in Irish biotech firm Amarin (AMRN +8.6%) is a Leerink Swann note speculating...

This news story has 1 comment:

Register or Login to rate comments »

serenas5 Comments (118)
 
I have held shares of AMRN for a few years adding to my long position on recent pullbacks. Because of the news or I should say lack of news I'm wondering what is really happening here. With a CEO who has been less than forthcoming and sitting on a product that tests say beat the current marketed product hands down with articles using the word blockbuster and several big pharma companys with products going off patent why haven't we heard of a takeover be it friendly or hostile.
Instead the concerns are being directed at patent concerns of Amarin's next product a potential heart drug candidate also given the blockbuster status.
I have been a big fan and investor of the pharma development sector
for about 10 years now and when phase 3 results are as positive as the marine and anchor trials combined with blockbuster status being attached the pps has been more than double the current price of Amarin.
I really feel I'm missing something here.
18 Mar 2012, 11:36 AM Reply Like